维普期刊资源整合服务平台（V6.5）

245篇 您的检索式：作者名="CHAPPLE CR"

选中清除导出查看参考文献查看引证文献引用追踪共13页首页上一页第1页下一页末页 /13 跳转

	题名	作者	年代	出处	被引量
1	Selective alpha 1-adrenorceptor antagonists in benign prostatic hyperplasia:rationale and clinical experience 显示文摘	Chapple CR	1996	Eur Urol1996，29，2：	1
2	A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome:results of the STAR trial显示文摘	Chapple CR Martinez-Garcia R Selvaggi L	2005	Eur Urol2005，48，3：	1
3	Transurethral implantation of silicone polymer for stress incontinence : evaluation of a porcine model and mechanism of action in vivo显示文摘	Radley SC Chapple CR Lee JA	2000	BJU Int2000，85，：	1
4	Silodosin: a new subtype se- lective alpha-1 antagonist for the treatment of lower urinary tract symp- toms in patients with benign prostatic hyperplasia 显示文摘	Osman NI Chapple CR Cruz F	2012	Expert Opin Pharmacother2012，13，14：	1
5	Alpha adrenoceptor subtypes in the human prostate显示文摘	Chapple CR Burt RP Ardersson PO	1994	Br J Urol1994，74，5：	1
6	Pharmacological treat-ment of overactive bladder:report from the International Consultationon Incontinence显示文摘	Andersson KE Chapple CR Cardozo L	2009	Curr Opin Urol2009，19，4：	1
7	Benign prostatic hyperplasia: treatment in primary care显示文摘	Patel AK Chapple CR	2006	BMJ2006，333，7567：	1
8	Beta3-adrenoceptors in urinary bladder显示文摘	Yamaguchi O Chapple CR	2007	Neurourology and Urodynamics2007，26，6：	1
9	Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation 显示文摘	Chapple CR Aubrey ML James S	1989	Br J Urol1989，，：	1
10	Haemodynamic evidence for cardiac stress during transurethral prostatectomy 显示文摘	Evans JW Singer M Chapple CR	1992	BMJ1992，304，6828：	1
11	Pharmacotherapy for benign prostatic hyper- plasia-the potential for alpha 1-adrenoceptor subtype- specific blockade 显示文摘	Chapple CR	1998	Br J Urol1998，81，1：	1
12	The treatment of vesicovaginal fistua显示文摘	Woo HH Rosario DJ chapple CR	1996	Eur Urol1996，29，1：	1
13	A comparison of the efficacy and tolerability of solifenacin succinate and extended release toherodine at treating overactive bladder syndrome:Results of the STAR trial显示文摘	Chapple CR Murtinez-Garcia R Selvaggi L	2005	Eur Urol2005，48，3：	1
14	The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia显示文摘	Chapple CR Smith D	1994	Br J Urol1994，73，4：	1
15	Treatment outcomes in the STAR study : a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg显示文摘	Chapple CR Fianu-Jonsson A Indig M	2007	Eur Urol2007，52，：	1
16	A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures显示文摘	Mangera A Patterson JM Chapple CR	2011	Eur Urol2011，59，5：	1
17	Which musca- rinic receptor is important in the bladder? 显示文摘	Yamanishi T Chapple CR Chess-Williams R	2001	World J Urol2001，19，5：	1
18	Randomized, trial of the once- daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder显示文摘	Chapple CR Rechberger T A1-Shukri S et double-blind placebo- and al	2004	BJU Int2004，93，：	1
19	The treatment of vesicovaginal fi stua显示文摘	Woo HH Rosario DJ Chapple CR		0，，：	1
20	Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and toherodine-controlled phase 2 dose-finding study显示文摘	Chapple CR Araeio P Bosch JL	2004	BJU Int2004，93，：	1

返回顶部每页显示：

共13页首页上一页第1页下一页末页 /13 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示